Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice (Q45359726)

13 December 2017

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice (English)

1 reference

13 December 2017

0 references

0 references

Najoua Dendouga

1

1 reference

13 December 2017

Michel Fochesato

2

1 reference

13 December 2017

Laurence Lockman

3

1 reference

13 December 2017

Sally Mossman

4

1 reference

13 December 2017

Sandra L Giannini

5

1 reference

13 December 2017

language of work or name

English

0 references

publication date

10 February 2012

1 reference

13 December 2017

1 reference

13 December 2017

30

1 reference

13 December 2017

20

1 reference

13 December 2017

3126-3135

1 reference

Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease

13 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Advances in the understanding of the pathogenesis and epidemiology of herpes zoster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Humoral and cellular immunity to varicella-zoster virus: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Dysregulation of human Toll-like receptor function in aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Aging of the innate immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Aging, immunity, and the varicella-zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Zoster vaccine: current status and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Distribution of varicella-zoster virus gpI and gpII and corresponding genome sequences in the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Human T Cells Recognize Multiple Epitopes of an Immediate Early/Tegument Protein (IE62) and Glycoprotein I of Varicella Zoster Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Kinetics and Viral Protein Specificity of the Cytotoxic T Lymphocyte Response in Healthy Adults Immunized with Live Attenuated Varicella Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Immunization with a DNA expression vector encoding the varicella zoster virus glycoprotein E (gE) gene via intramuscular and subcutaneous routes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Impact of varicella vaccine on varicella-zoster virus dynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Immunofluorescence analysis of T-cell responses in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Mechanism of action of clinically approved adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Targeting the innate immune response with improved vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

The perfect mix: recent progress in adjuvant research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Gain and loss of T cell subsets in old age--age-related reshaping of the T cell repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Vaccination in the elderly: an immunological perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

Biology of immune responses to vaccines in elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

A mouse model for varicella-zoster virus latency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.088

10.1016/J.VACCINE.2012.01.088

7 January 2021

Identifiers

DOI

1 reference

13 December 2017

1 reference